Johnson & Johnson Construction in Progress, Gross
Johnson & Johnson (JNJ) had Construction in Progress, Gross of $4.32 billion as of 2021-01-03, per its 10-K filed 2021-02-22.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization
us-gaap:ConstructionInProgressGross · last filed 2021-02-22
- 2021-01-03: Construction in Progress, Gross $4.32B.
- 2019-12-29: Construction in Progress, Gross $3.64B.
- 2018-12-30: Construction in Progress, Gross $3.88B.
- 2017-12-31: Construction in Progress, Gross $3.45B.
| Period end | Construction in Progress, Gross |
|---|---|
| 2021-01-03 | $4.32B 10-K · filed 2021-02-22 |
| 2019-12-29 | $3.64B 10-K · filed 2021-02-22 |
| 2018-12-30 | $3.88B 10-K · filed 2020-02-18 |
| 2017-12-31 | $3.45B 10-K · filed 2019-02-20 |
| 2017-01-01 | $3.35B 10-K · filed 2018-02-21 |
| 2016-01-03 | $3.53B 10-K · filed 2017-02-27 |
| 2014-12-28 | $3.60B 10-K · filed 2016-02-24 |
| 2013-12-29 | $3.30B 10-K · filed 2015-02-24 |
| 2012-12-30 | $2.74B 10-K · filed 2014-02-21 |
| 2012-01-01 | $2.50B 10-K · filed 2013-02-22 |
| 2011-01-02 | $2.58B 10-K · filed 2012-02-23 |
| 2010-01-03 | $2.52B 10-K · filed 2011-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |